Roivant Sciences Ltd. (ROIV)
41.85
+0.66
(+1.60%)
USD |
NASDAQ |
Nov 11, 16:00
41.03
-0.82
(-1.96%)
After-Hours: 20:00
Roivant Sciences Net Income (Quarterly) : -152.97M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -152.97M |
| June 30, 2026 | -290.61M |
| March 31, 2026 | 355.74M |
| December 31, 2025 | -313.70M |
| September 30, 2025 | -166.04M |
| June 30, 2025 | -273.91M |
| March 31, 2025 | -252.38M |
| December 31, 2024 | -208.94M |
| September 30, 2024 | -236.84M |
| June 30, 2024 | -31.60M |
| March 31, 2024 | -94.96M |
| December 31, 2023 | 5.131B |
| Date | Value |
|---|---|
| September 30, 2023 | -244.64M |
| June 30, 2023 | -327.84M |
| March 31, 2023 | -175.42M |
| December 31, 2022 | -384.90M |
| September 30, 2022 | -315.92M |
| June 30, 2022 | -353.78M |
| March 31, 2022 | -291.31M |
| December 31, 2021 | -306.08M |
| September 30, 2021 | -225.64M |
| June 30, 2021 | -101.08M |
| March 31, 2021 | -563.16M |
| March 31, 2020 | -75.74M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Bicycle Therapeutics Plc | -10.47M |
| Immunovant, Inc. | -97.25M |
| Adaptimmune Therapeutics Plc | -- |
| Kiniksa Pharmaceuticals International Plc | 47.34M |
| Autolus Therapeutics Plc | -55.06M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 35.12M |
| Total Expenses (Quarterly) | 242.50M |
| EPS Diluted (Quarterly) | -0.2869 |
| Enterprise Value | 26.76B |
| Gross Profit Margin (Quarterly) | 88.75% |
| Profit Margin (Quarterly) | -435.6% |
| Earnings Yield | -1.34% |
| Normalized Earnings Yield | -3.087 |